Chronic Lymphocytic Leukemia

Disease State Hub

From the Journal

Dermatologic disorders

Dermatologic disorders

12/06/2018

A 62-year-old African American woman with history of type 2 diabetes mellitus and psoriasis presented with a tender, pruritic, 1.5 × 1.5-cm, ulcerative nodule with peripheral hyperpigmentation and...

12/06/2018

Chronic Lymphocytic Leukemia

Asymptomatic Leukocytosis in an Elderly Man

11/17/2005

An 81-year-old man is seen for follow-up of leukocytosis detected during a recent hospitalization for community-acquired pneumonia.

11/17/2005

Research Summaries

FDA Alert

FDA Grants Accelerated Approval for First CAR-T Cell Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/22/2024

Anthony Calabro, MA

The FDA previously approved lisocabtagene maraleucel as a second-line treatment option for adult patients with large B-cell lymphoma in June 2022.

04/22/2024

research summary

research summary

Risk of Infections Among Patients With AML, CLL Treated With Venetoclax

03/26/2024

Leigh Precopio

Researchers examined if venetoclax—a therapy commonly used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia—was associated with an increased risk of opportunistic infections,...

03/26/2024

Conference Coverage

Study Finds Slightly Lower Risk of Richter Transformation for Patients With Chronic Lymphocytic Leukemia in the “Novel Agent Era”

03/13/2024

Anthony Calabro, MA

The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...

03/13/2024

Conference Coverage

Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Improves PFS Compared With Venetoclax Alone

02/23/2024

Anthony Calabro, MA

Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...

02/23/2024

Conference Coverage

Ibrutinib Dose Adjustments Do Not Impact Time to Next Treatment For Patients With Chronic Lymphocytic Leukemia

01/31/2024

Anthony Calabro, MA

Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...

01/31/2024

April 2024

Current Issue

April 2024

Volume 64

Issue 4